Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

November 1, 2017
William R. Berry, MD

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Before LHRH antagonists, there was a concern for patients who presented with metastatic disease, particularly metastatic disease in the bone, states Berry. Many of these patients would experience a surge of bone pain after starting therapy.

There is an indication to use the antagonist as they present with fewer symptoms than agonists, explains Berry.